Dr Reddy’s ties up with US firm for resuscitative therapy


New Delhi: Dr Reddy's has entered into a license agreement with US-based Pharmaz biopharmaceutical companyfirst class commercialization innovative medicine Centhaquin in India.
Developed by Pharmaz, Centhaquin is a resuscitation agent currently approved by the Drugs Controller General of India (DCGI) for the treatment of hypovolemic shock, a company statement said.
As per the agreement, Dr. Reddy's has received the exclusive right to market and distribute Centhaquin in India. Pharmaz will be entitled to advance payment and royalties.
India is the first global region in which Centhaquin (Lifequin) is being launched immediately.
MV Ramana, CEO Branded Markets (India & Emerging Markets), Dr. Reddy's said, “Clinical studies of Lifaquin have demonstrated significantly improved and promising results, making it a potential add-on medicine in the management of hypovolemic shock And it can be expanded.” The current standard of care for its treatment in India.”
Centhaquin is a frontline therapy used alongside standard of care and is well positioned to fill a significant unmet need as a pharmacologically active resuscitation agent. It states that hypovolemic shock can be caused by decreased circulating blood volume from blood or fluid loss due to trauma, gastrointestinal bleeding, major surgery, postpartum hemorrhage, diarrhea, or vomiting.

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *